Cardio Diagnostics Holdings, Inc.

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) is an artificial-intelligence-driven cardiovascular diagnostics company that entered the public markets through its merger with Mana Capital Acquisition Corp., a SPAC sponsored by Mana Capital, LLC that completed its IPO in 2021. The combined company, operating in the healthcare and precision medicine sector, focuses on epigenetic biomarker-based testing for cardiovascular disease detection and risk assessment. On August 7, 2026, Cardio Diagnostics filed a Form DEFA14A — additional definitive proxy materials — signaling active shareholder engagement on a pending matter requiring stockholder action. Investors and analysts tracking post-merger SPAC developments in the diagnostics space can access the full CDIO filing history and company data by signing up at SpacDesk.